First iPS Cell Trial for Heart Disease Raises Excitement …
Posted: May 12, 2020 at 12:52 pm
Early next year, a small clinical trial will begin in Japan, marking the first time reprogrammed stem cells will be deployed to help regenerate injured hearts. A team led by Osaka University cardiac surgeon Yoshiki Sawa will implant sheetseach consisting of 100 million stem-cell derived cardiomyocytesonto the hearts of three patients with advanced heart failure.
Its a big deal theyve gotten approval to do this, remarks Jalees Rehman, associate professor of medicine and pharmacology at the University of Illinois at Chicago.
The cardiac study is one of the first few clinical applications of induced pluripotent stem (iPS) cells, the first being an iPS cell-based treatment of macular degeneration of the eye, which also took place in Japan.While it is a big deal to pioneer such a technology clinically, the trial also has its risks, unknowns, and critics.
Japans health ministry conditionally approved the heart experiment in May, with the goal of assessing the safety of the procedure. If the first trial and a later one enrolling 10 patients prove successful, the treatment will be made commercially available soon under a new fast-track system in Japan designed to speed up the development of regenerative therapies.
Since the trial was announced, several Japanese researchers have voiced their concerns in comments and correspondences in Nature. One of them, Akira Akayabashi, a professor of biomedical ethics at Tokyo University, notes that the trail participants will receive iPS-derived cells from a donor, instead of from their own tissue, and will have to be placed on immunosuppressants for three months to prevent rejection. It will add extra burden of using immune suppressants to heart failure patients who are already suffering, he tells The Scientist.
Im really happy there are countries in the world that are really prioritizing the role of stem cells.
Phillip Yang, Stanford University
Sawa says that creating cardiomyocytes derived from a patients own cells is not always an option, because the reprogramming process takes a long time. Additionally, providing off-the-shelf treatments is a more feasible route to address heart failure, he says. Cell therapy [using a patients own cells] seems to be not suitable for industrialization, he says.
While preclinical work with iPS cells has proven effective in improving heart function in mice, pig, and monkey models, its not quite clear by which mechanism the cells are promoting muscle regeneration. Its still unknown whether these cells actually integrate into the heart and become beating heart cells, or whether they just release factors and help existing heart cells, Rehman says.
Sawas research in pigs suggests that iPS cellderived cardiomyocytes promote regeneration of the heart by secreting certain cytokines that stimulate the native heart muscle to grow, he explains. In contrast to skeletal myoblasts taken from patients thighswhich he is testing in another clinical trial for heart failurethe cardiac cells derived from iPS cells have additional cytokines [that] seem to be very helpful, he tells The Scientist.
The use of the cell sheets [in humans] is intriguing, says Phillip Yang, an associate professor of cardiovascular medicine at Stanford University. Ultimately, [the procedure] would help find out if this method of application will work or not, he says. However, if the secretions are what helps repair the heart, he questions why implanting the cells is necessary. Instead, Yang and others are studying potential regenerative therapies by isolating and injecting these regenerative factors into pigs hearts.
Yang says he is most concerned with the survival of the reprogrammed cardiomyocytes within the heart. The likelihood of a cell, a very fragile, iPS-derived cell, surviving in an area where there is a large amount of injury, lack of blood, lack of oxygen supply is very low, he says. If they disappear quickly, the treatment wont be effective.
Another concern is that implanting the cells as a sheet will likely involve open-heart surgery. Because they are making a sheet of cells, they cannot just inject it into the heart, Rehman says, adding that injecting the cells is a much less invasive approach. And given that the patients are already suffering from severe heart failure, is the surgery itself going to be a risk for them? he asks.
There are other risks associated with introducing the new cells into the heart, Rehman says. They could potentially become tumorigenic, because they originate from a very proliferative cell type. The possibility of heart rhythm problems could also be an issue, he says. This became apparent when researchers at the University of Washington injected monkey hearts with cardiomyocytes derived from human embryonic stem cells.
Regardless of the concerns, Yang is excited to see the outcome of Sawas trial, and the new information it will bring to the field.
Im really happy there are countries in the world that are really prioritizing the role of stem cells, Yang says. Since stem cell researcher Shinya Yamanaka received the Nobel prize for the development of iPS cells in 2012, the field has been booming in Japan. Four years ago, the Japanese government decided to put more than $1 billion USD towards regenerative medicine research, a quarter of which goes to a project to develop stocks of iPS cells for biomedical research.
If there was a really effective treatment for heart failurewhich is still the number one cause of hospital admission in this country and so forthI think that would be great, Yang says. But whether iPS-derived cardiomyocytes is the answer, and much better than anything else, that Im not so sure.
Correction (November 14): A previous version of this article incorrectly stated that this study is the second-ever clinical applications of iPS cells, when it is in fact one of several.The Scientistregrets the error.
See the original post:
First iPS Cell Trial for Heart Disease Raises Excitement ...
- Research and therapy with induced pluripotent stem cells ... - December 19th, 2020
- Global Induced Pluripotent Stem Cells (iPSCs) Market Expectable to Exceed Global Market Revenue, Size, Segments and Market Competition Trend to... - December 14th, 2020
- Evotec and Sartorius Partner with Start-Up Curexsys on IPSC-Based Therapeutic Exosome Approach - BioSpace - December 10th, 2020
- A Potential Therapy for One of the Leading Causes of Heart Disease - PRNewswire - December 10th, 2020
- Multiple sclerosis iPS-derived oligodendroglia conserve their properties to functionally interact with axons and glia in vivo - Science Advances - December 6th, 2020
- The Stem Cell-Derived Cells market to Scale new heights in the next decade - Khabar South Asia - November 27th, 2020
- The Stem Cell-Derived Cells Market to witness explicit growth from 2019 and 2029 - The Haitian-Caribbean News Network - November 27th, 2020
- Stem Cells Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted by the Competitors | (2020-2027),... - November 26th, 2020
- Stem Cells Market 2020: Rising with Immense Development Trends across the Globe by 2027 - The Market Feed - November 26th, 2020
- U.S. engineering firms ride on waves of innovation - Building Design + Construction - November 26th, 2020
- The Stem Cell-Derived Cells market to be in conjunction to growth from 2020 to 2030 - PRnews Leader - October 28th, 2020
- Stem Cell-Derived Cells Market to Expand at a Healthy CAGR of XX% Between and 2019 2029 - Eurowire - October 25th, 2020
- Stem Cell-Derived Cells Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2019 - 2029 - Stock Market Funda - October 4th, 2020
- Ghosh Addresses Brentuximab Vedotin Use in Advanced Hodgkin Lymphoma - Targeted Oncology - September 30th, 2020
- Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 Manufacturer Analysis, Technology Advancements, Industry Scope and Forecast to 2027||Fate... - September 22nd, 2020
- Convergence: EMA close to finalizing guidance for advanced therapies - Regulatory Focus - September 18th, 2020
- Researchers ID Role of Protein in Development of New Hearing Hair Cells - Lab Manager Magazine - September 18th, 2020
- In-depth Research On Media, Sera And Reagents In Biotechnology Market Insights, And Forecast Till 2018-2023 - Scientect - September 6th, 2020
- Optimized Freezing Solutions for Clinical Application of Cell Therapy Products - technologynetworks.com - September 2nd, 2020
- Stem Cell-Derived Cells Market Forecast to 2025: Global Industry Analysis by Top Players, Types, Key Regions and Applications - The Scarlet - September 2nd, 2020
- Cell Therapy Processing Market is Booming Worldwide to Show Significant Growth by 2026 Cell Therapies Pty Ltd,Invitrx Inc.,Lonza Ltd,Merck & Co.,... - August 21st, 2020
- On the move at the OneAZ, Spencer Fane, UArizona - AZ Big Media - August 21st, 2020
- 3D Cell Cultures Industry Report 2020-2025: Impact of COVID-19 on the World of Cell Culture - PRNewswire - August 19th, 2020
- Stem Cell-Derived Cells Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2019 2029 - Owned - August 16th, 2020
- Opportunities in the Global Induced Pluripotent Stem Cell (iPS Cell) Industry - PRNewswire - August 12th, 2020
- Stem Cell-Derived Cells Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2019 2029 - Bulletin Line - August 2nd, 2020
- Hitachi and ThinkCyte to Develop an AI-driven Cell Analysis | ARC Advisory - ARC Viewpoints - July 8th, 2020
- Hitachi and ThinkCyte announce collaboration to develop an AI-driven cell analysis and sorting system - BioSpace - July 1st, 2020
- 2020-2024 Global Regenerative Medicine Market with Impact Analysis of COVID-19, Production, Revenue, Demand & Applications - Apsters News - July 1st, 2020
- Global Stem Cells Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By MRE - Cole of Duty - June 29th, 2020
- Global Regenerative Medicine Market: Size and Forecast with Impact Analysis of COVID-19 (2020-2024) - Cole of Duty - June 29th, 2020
- Global Stem Cell Therapy Market 2020: Size, Share, Growth Rate, Revenue and Volume, Key-Players, Top Regions and Forecast Till 2025 - Cole of Duty - June 22nd, 2020
- Global Regenerative Medicine Market (2020 to 2024) - Size & Forecast with Impact Analysis of COVID-19 - ResearchAndMarkets.com - Business Wire - June 18th, 2020
- Excellent growth of Human Embryonic Stem Cells Market- Comprehensive study by key players: Astellas Pharma Inc/ Ocata Therapeutics, Stemcell... - June 5th, 2020
- Global Stem Cell Partnering Deals Collection (2010-2020): Access to Headline, Upfront, Milestone and Royalty Data - PRNewswire - May 18th, 2020
- Global Stem Cell Partnering Terms and Agreements 2010-2020 - ResearchAndMarkets.com - Business Wire - May 17th, 2020
- AgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update - Business Wire - May 16th, 2020
- Induced Pluripotent Stem Cell (iPSC) Media and Reagents ... - May 12th, 2020
- Researchers use cell therapy to recover damaged brain areas in mice that suffered - Mirage News - April 26th, 2020
- Evotec Regains Global Rights to Beta Cell Replacement Therapy - Yahoo Finance - April 22nd, 2020
- Researchers restore sight in mice by turning skin cells into light-sensing eye cells - National Institutes of Health - April 15th, 2020
- Chimeric Antigen Receptor (CAR) T-Cell Therapy Market 2020: Professional Survey & Competitive Dynamics Mustang Bio Inc., iCell Gene Therapeutics,... - April 12th, 2020
- Evotec Expands its iPSC-Based Cell Therapy Platform EVOcells Through Licensing Agreement with panCELLa | More News | News Channels -... - April 6th, 2020
- Evotec partners with panCELLa to enhance cell therapy plaform - ITResearchBrief.com - April 6th, 2020
- Evotec Expands its iPSC-Based Cell Therapy Platform EVOcells Through Licensing Agreement with panCELLa - BioSpace - April 2nd, 2020
- AgeX Therapeutics Reports Fourth Quarter and Annual 2019 Financial Results and Provides Business Update - Business Wire - April 1st, 2020
- Stem Cell-Derived Cells Value Projected to Expand by 2019-2025 - 3rd Watch News - March 21st, 2020
- Global induced pluripotent stem cells market is expected to grow with a CAGR of 8.6% over the forecast period from 2019-2025 - GlobeNewswire - March 15th, 2020
- NIH launches first U.S. clinical trial of patient-derived ... - March 11th, 2020
- Eye health: Testing the safety of stem cell therapy for age-related macular degeneration - Open Access Government - March 11th, 2020
- Why are Pluripotent Stem Cells Important? Boston ... - March 8th, 2020
- AgeX Therapeutics Researchers Publish Paper on the Age Reprogramming of Super-Centenarian Cells - Yahoo Finance - March 1st, 2020
- CAR T-Cell Therapy: Genetically Programming the Immune System to Attack Malignant Cells - Pharmacy Times - February 25th, 2020
- Stem Cell Therapy Contract Manufacturing Industry, 2019-2030 - Availability of Cutting-Edge Tools & Technologies has Emerged as a Differentiating... - February 17th, 2020
- Surge in the Adoption of Stem Cell-Derived Cells to Fuel the Growth of the Stem Cell-Derived Cells Market Through the Assessment Period 2019 2029 -... - February 16th, 2020
- Osaka University transplants iPS cell-based heart cells in world's first clinical trial - The Japan Times - January 30th, 2020
- Osaka University-based team successfully conducts first transplantation of cardiac muscle cells around the globe - Medical Herald - January 30th, 2020
- Kyoto University team gets OK from ministry for plan to transplant iPS-derived cartilage into knee joints - The Japan Times - January 25th, 2020
- The Kyoto University team's plan to transplant iPS cartilage into knee joints is OK - gotech daily - January 25th, 2020
- Update on stem cell treatment cost for 2018 from ongoing ... - January 21st, 2020
- Psychiatric body condemns use of stem cell therapies to treat psychiatric disorders - Moneycontrol.com - January 21st, 2020
- Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines - BioSpace - January 17th, 2020
- Why stem cells could be the medical innovation of the century - World Economic Forum - January 16th, 2020
- Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines - Business Wire - January 16th, 2020
- Where Are They Now? Top 3 Biotech Startups From NextGen Bio Class of 2018 - BioSpace - January 12th, 2020
- Treating a tricky skin disease | Interviews - The Naked Scientists - December 20th, 2019
- Global Stem Cell Therapy Market to Surpass US$ 40.3 Billion by 2027 Coherent Market Insights - Business Wire - December 17th, 2019
- Lineage Cell Therapeutics and AgeX Therapeutics Announce Issuance of US Patent for Method of Generating Induced Pluripotent Stem Cells - BioSpace - December 11th, 2019
- AgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells - Yahoo... - December 11th, 2019
- Patent Granted To Lineage & AgeX - Anti Aging News - December 11th, 2019
- Global Cell Therapy Processing Market Growth, Demand, Industry Verticals, and Forecast upto 2022 - News Description - December 8th, 2019
- Takeda sees cell, gene therapy in its future. Is it too late? - BioPharma Dive - November 21st, 2019
- Novel Cell Sorting and Separation Markets, 2030 - P&T Community - October 9th, 2019
- Stem Cell-Derived Cells Market to Record an Exponential CAGR by 2025 - NewsVarsity - September 22nd, 2019
- Stem Cell-Derived Cells Market to Record an Exponential CAGR by 2025 - Commerce Gazette - September 20th, 2019
- Interview: BIOLIFE4D is The First US Company to Bioprint a Mini-Heart (for Cardiotoxicity Testing) - 3DPrint.com - September 20th, 2019
- Genetic Tests Offered (all nonprofit) | The John and ... - June 7th, 2019
- The addition of human iPS cell-derived neural progenitors ... - June 3rd, 2019
- iPS Cells for Disease Modeling and Drug Discovery - June 3rd, 2019
- CloneR hPSC Cloning Supplement - Stemcell Technologies - May 26th, 2019